Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?

被引:62
|
作者
Alshamrani, Ali A. [1 ]
机构
[1] King Saud Univ, Dept Pharmacol & Toxicol, Coll Pharm, Riyadh, Saudi Arabia
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
microRNA; ovarian cancer; proliferation; biomarkers; chemoresistance; diagnosis; prognosis; target genes; GLUTATHIONE-S-TRANSFERASE; SUPPRESSES TUMOR-GROWTH; PROMOTES CELL-GROWTH; CISPLATIN RESISTANCE; DOWN-REGULATION; MIR-200; FAMILY; UP-REGULATION; ENHANCES CHEMOSENSITIVITY; MULTIDRUG-RESISTANCE; INHIBITS METASTASIS;
D O I
10.3389/fonc.2020.01084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is one of the top gynecological malignancies that cause deaths among females in the United States. At the molecular level, significant progress has been made in our understanding of ovarian cancer development and progression. MicroRNAs (miRNAs) are short, single-stranded, highly conserved non-coding RNA molecules (19-25 nucleotides) that negatively regulate target genes post-transcriptionally. Over the last two decades, mounting evidence has demonstrated the aberrant expression of miRNAs in different human malignancies, including ovarian carcinomas. Deregulated miRNAs can have profound impacts on various cancer hallmarks by repressing tumor suppressor genes. This review will discuss up-to-date knowledge of how the aberrant expression of miRNAs and their targeted genes drives ovarian cancer initiation, proliferation, survival, and resistance to chemotherapies. Understanding the mechanisms by which these miRNAs affect these hallmarks should allow the development of novel therapeutic strategies to treat these lethal malignancies.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Three decades of underground research laboratories: what have we learned?
    Delay, Jacques
    Bossart, Paul
    Ling, Li Xiang
    Blechschmidt, Ingo
    Ohlsson, Mats
    Vinsot, Agnes
    Nussbaum, Christophe
    Maes, Norbert
    CLAYS IN NATURAL AND ENGINEERED BARRIERS FOR RADIOACTIVE WASTE CONFINEMENT, 2014, 400 : 7 - 32
  • [32] What have we learned from five decades of neutralization research?
    Maruna, S
    Copes, H
    CRIME AND JUSTICE: A REVIEW OF RESEARCH, VOL 32, 2005, 32 : 221 - 320
  • [33] Fontan operation after 3 decades - What we have learned
    Gersony, Welton M.
    CIRCULATION, 2008, 117 (01) : 13 - 15
  • [34] Cancer Chemoprevention: What Have we Learned?
    Yang C.S.
    Wang H.
    Dan V.
    Filippo S.S.
    Current Pharmacology Reports, 2017, 3 (6) : 409 - 422
  • [35] Diabetic nephropathy - what have we learned in the last three decades?
    Odoni, G
    Ritz, E
    JOURNAL OF NEPHROLOGY, 1999, 12 : S120 - S124
  • [36] Genetics of Obesity: What We Have Learned Over Decades of Research
    Bouchard, Claude
    OBESITY, 2021, 29 (05) : 802 - 820
  • [37] Cancer clusters: what have we learned?
    Stewart, B. W.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (01) : 5 - 6
  • [38] Endometriosis-associated ovarian cancer: What have we learned so far?
    Herreros-Villanueva, M.
    Chen, Chih-Chieh
    Tsai, Eing-Mei
    Er, Tze-Kiong
    CLINICA CHIMICA ACTA, 2019, 493 : 63 - 72
  • [39] MicroRNAs and cancer: what we know and what we still have to learn
    George A Calin
    Genome Medicine, 1
  • [40] MicroRNAs and cancer: what we know and what we still have to learn
    Calin, George A.
    GENOME MEDICINE, 2009, 1